Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
Status:
Completed
Trial end date:
2017-11-02
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, safety and activity study of lenvatinib in subjects with
KIF5B-RET-positive adenocarcinoma of the lung and other confirmed RET translocations. At
least 20 subjects with KIF5B-RET and other RET translocations will be treated and will
receive lenvatinib at a starting dose of 24 mg orally, once per day. The study will consist
of 3 phases: The Pretreatment Phase, The Treatment Phase and the Extension Phase. The
Pretreatment Phase will include screening procedures and eligibility assessments. The
Pretreatment Phase consists of a Screen 1, Screen 2 and Baseline Period. The Treatment Phase
will begin when the subject has met all eligibility criteria on Day 1 of the first Treatment
Cycle. The Treatment Phase contains the Treatment and Follow-up Periods. The Extension Phase
will begin for subjects who received treatment in the study (either in the Treatment Period
or Follow-up Period) at the time of database cutoff.